Smart.Molecules

Bridging innovation from discovery to clinic.

Smart.Molecules

Bridging innovation from discovery to clinic.

Smart.Molecules

Bridging innovation from discovery to clinic.

From vision to company.

We help turn scientific breakthroughs into successful businesses. Partnering with early-stage biotech, we accelerate innovation from discovery to clinic – from company building and start-up coaching to strategic consulting and build-to-buy models. With our expertise in platform technology building, we lay the foundations for long-term value creation.

Sharpening assets.

Strong assets need a clear identity. We analyze early-stage projects, define target product profiles, and develop intellectual property strategies that protect innovation. By focusing on USP and differentiation, we make sure each asset is positioned to stand out in a competitive landscape.

AI meets medicinal chemistry.

Smarter design leads to better drugs. Our AI-enabled drug design accelerates discovery and optimizes molecular properties. Combined with deep medicinal chemistry expertise, we ensure the right choices in in vitro and in vivo assay selection and create optimized testing funnels that reduce time and cost.

From vision to company.

We help turn scientific breakthroughs into successful businesses. Partnering with early-stage biotech, we accelerate innovation from discovery to clinic – from company building and start-up coaching to strategic consulting and build-to-buy models. With our expertise in platform technology building, we lay the foundations for long-term value creation.

Sharpening assets.

Strong assets need a clear identity. We analyze early-stage projects, define target product profiles, and develop intellectual property strategies that protect innovation. By focusing on USP and differentiation, we make sure each asset is positioned to stand out in a competitive landscape.

AI meets medicinal chemistry.

Smarter design leads to better drugs. Our AI-enabled drug design accelerates discovery and optimizes molecular properties. Combined with deep medicinal chemistry expertise, we ensure the right choices in in vitro and in vivo assay selection and create optimized testing funnels that reduce time and cost.

From vision to company.

We help turn scientific breakthroughs into successful businesses. Partnering with early-stage biotech, we accelerate innovation from discovery to clinic – from company building and start-up coaching to strategic consulting and build-to-buy models. With our expertise in platform technology building, we lay the foundations for long-term value creation.

Sharpening assets.

Strong assets need a clear identity. We analyze early-stage projects, define target product profiles, and develop intellectual property strategies that protect innovation. By focusing on USP and differentiation, we make sure each asset is positioned to stand out in a competitive landscape.

AI meets medicinal chemistry.

Smarter design leads to better drugs. Our AI-enabled drug design accelerates discovery and optimizes molecular properties. Combined with deep medicinal chemistry expertise, we ensure the right choices in in vitro and in vivo assay selection and create optimized testing funnels that reduce time and cost.

Driving translation.

We guide projects seamlessly from preclinical research to IND-enabling studies. Our capabilities span in vitro and in vivo pharmacology, histology and histopathology, biomarker discovery, and translational science. This integrated approach generates robust data packages that de-risk development and enable confident progression toward the clinic.

Broad modalities.

Our expertise covers a wide range of therapeutic modalities. We design and develop small molecules, ADCs, biologics, and immunotherapies, with a focus on both CNS-penetrant and peripherally restricted drugs. We also support innovative delivery formats such as eye drops.

Winning grants.

We help unlock non-dilutive funding by supporting the full grant lifecycle. From grant conceptualisation and proposal proof-reading to partner identification, consortium structuring, and project management, we provide the expertise needed to win and deliver large-scale collaborative funding initiatives.

Driving translation.

We guide projects seamlessly from preclinical research to IND-enabling studies. Our capabilities span in vitro and in vivo pharmacology, histology and histopathology, biomarker discovery, and translational science. This integrated approach generates robust data packages that de-risk development and enable confident progression toward the clinic.

Broad modalities.

Our expertise covers a wide range of therapeutic modalities. We design and develop small molecules, ADCs, biologics, and immunotherapies, with a focus on both CNS-penetrant and peripherally restricted drugs. We also support innovative delivery formats such as eye drops.

Winning grants.

We help unlock non-dilutive funding by supporting the full grant lifecycle. From grant conceptualisation and proposal proof-reading to partner identification, consortium structuring, and project management, we provide the expertise needed to win and deliver large-scale collaborative funding initiatives.

Driving translation.

We guide projects seamlessly from preclinical research to IND-enabling studies. Our capabilities span in vitro and in vivo pharmacology, histology and histopathology, biomarker discovery, and translational science. This integrated approach generates robust data packages that de-risk development and enable confident progression toward the clinic.

Broad modalities.

Our expertise covers a wide range of therapeutic modalities. We design and develop small molecules, ADCs, biologics, and immunotherapies, with a focus on both CNS-penetrant and peripherally restricted drugs. We also support innovative delivery formats such as eye drops.

Winning grants.

We help unlock non-dilutive funding by supporting the full grant lifecycle. From grant conceptualisation and proposal proof-reading to partner identification, consortium structuring, and project management, we provide the expertise needed to win and deliver large-scale collaborative funding initiatives.

Flexible partnerships.

We collaborate in the way that fits your project best: part-time roles for ongoing support, project-based roles for defined milestones, or ad hoc consulting for targeted input.

Success-oriented and lean.

Our model is success-oriented, lean, and resource-efficient. We help you maximize outcome while minimizing overhead.

Remote-first, on-site when needed.

We work remotely by default, but are available for on-site team meetings whenever needed.

Flexible partnerships.

We collaborate in the way that fits your project best: part-time roles for ongoing support, project-based roles for defined milestones, or ad hoc consulting for targeted input.

Success-oriented and lean.

Our model is success-oriented, lean, and resource-efficient. We help you maximize outcome while minimizing overhead.

Remote-first, on-site when needed.

We work remotely by default, but are available for on-site team meetings whenever needed.

Flexible partnerships.

We collaborate in the way that fits your project best: part-time roles for ongoing support, project-based roles for defined milestones, or ad hoc consulting for targeted input.

Success-oriented and lean.

Our model is success-oriented, lean, and resource-efficient. We help you maximize outcome while minimizing overhead.

Remote-first, on-site when needed.

We work remotely by default, but are available for on-site team meetings whenever needed.

Unique Grant Opportunities – Partnering with an EU Prime Location

TOGAPHARMA, as a Bulgarian OOD, is fully embedded in the European Union and brings unique advantages to international grant applications. By partnering with us, you automatically fulfill EU eligibility for major programs such as Horizon Europe, Digital Europe, Erasmus+, or EIT Health. Our setup enables higher funding rates and budget efficiency, while also strengthening geographic diversity in consortia. As a “Widening Participation Country,” Bulgaria offers a strategic position that increases the competitiveness of proposals and balances regional representation — making us a prime partner for successful international grant applications.

Unique Grant Opportunities – Partnering with an EU Prime Location

TOGAPHARMA, as a Bulgarian OOD, is fully embedded in the European Union and brings unique advantages to international grant applications. By partnering with us, you automatically fulfill EU eligibility for major programs such as Horizon Europe, Digital Europe, Erasmus+, or EIT Health. Our setup enables higher funding rates and budget efficiency, while also strengthening geographic diversity in consortia. As a “Widening Participation Country,” Bulgaria offers a strategic position that increases the competitiveness of proposals and balances regional representation — making us a prime partner for successful international grant applications.

Unique Grant Opportunities – Partnering with an EU Prime Location

TOGAPHARMA, as a Bulgarian OOD, is fully embedded in the European Union and brings unique advantages to international grant applications. By partnering with us, you automatically fulfill EU eligibility for major programs such as Horizon Europe, Digital Europe, Erasmus+, or EIT Health. Our setup enables higher funding rates and budget efficiency, while also strengthening geographic diversity in consortia. As a “Widening Participation Country,” Bulgaria offers a strategic position that increases the competitiveness of proposals and balances regional representation — making us a prime partner for successful international grant applications.

Therapeutic Areas We Cover

We support programs in CNS, Oncology, Inflammation, Cardiovascular & Cardiometabolic, and Ophthalmology — combining breadth of expertise with translational depth.

CNS – Tackling the Most Complex Diseases

We help optimize CNS-penetrant drugs for neurodegeneration and neuroinflammation, ensuring effective brain delivery and translational success.

Oncology – Precision Across Cancer Types

We help advance innovative approaches and therapies in solid tumors and haematological malignancies. We especially focus on metastases including the CNS to translate science into patient benefit.

Therapeutic Areas We Cover

We support programs in CNS, Oncology, Inflammation, Cardiovascular & Cardiometabolic, and Ophthalmology — combining breadth of expertise with translational depth.

CNS – Tackling the Most Complex Diseases

We help optimize CNS-penetrant drugs for neurodegeneration and neuroinflammation, ensuring effective brain delivery and translational success.

Oncology – Precision Across Cancer Types

We help advance innovative approaches and therapies in solid tumors and haematological malignancies. We especially focus on metastases including the CNS to translate science into patient benefit.

Therapeutic Areas We Cover

We support programs in CNS, Oncology, Inflammation, Cardiovascular & Cardiometabolic, and Ophthalmology — combining breadth of expertise with translational depth.

CNS – Tackling the Most Complex Diseases

We help optimize CNS-penetrant drugs for neurodegeneration and neuroinflammation, ensuring effective brain delivery and translational success.

Oncology – Precision Across Cancer Types

We help advance innovative approaches and therapies in solid tumors and haematological malignancies. We especially focus on metastases including the CNS to translate science into patient benefit.

Cardiovascular & Cardiometabolic – Protecting the Heart and Beyond

We help drive the development of cardiovascular and metabolic drugs with next-generation molecules aimed at improving outcomes in widespread conditions.

Inflammation – Controlling the Immune Storm

From IBD and arthritis to neuroinflammation, we help develop therapies that rebalance the immune system and bring lasting relief in chronic diseases.

Ophthalmology – Focused on Eye Health

We help advance treatments for ocular allergy and inflammation, leveraging small molecules and innovative delivery systems such as eye drops.

Cardiovascular & Cardiometabolic – Protecting the Heart and Beyond

We help drive the development of cardiovascular and metabolic drugs with next-generation molecules aimed at improving outcomes in widespread conditions.

Inflammation – Controlling the Immune Storm

From IBD and arthritis to neuroinflammation, we help develop therapies that rebalance the immune system and bring lasting relief in chronic diseases.

Ophthalmology – Focused on Eye Health

We help advance treatments for ocular allergy and inflammation, leveraging small molecules and innovative delivery systems such as eye drops.

Cardiovascular & Cardiometabolic – Protecting the Heart and Beyond

We help drive the development of cardiovascular and metabolic drugs with next-generation molecules aimed at improving outcomes in widespread conditions.

Inflammation – Controlling the Immune Storm

From IBD and arthritis to neuroinflammation, we help develop therapies that rebalance the immune system and bring lasting relief in chronic diseases.

Ophthalmology – Focused on Eye Health

We help advance treatments for ocular allergy and inflammation, leveraging small molecules and innovative delivery systems such as eye drops.

Michael Thormann, PhD – CEO

linkedin | researchgate

He holds a PhD in Biochemistry and has more than 25 years of experience in drug discovery and company building. As founder and long-term CEO/CSO of Origenis GmbH, he successfully guided multiple assets from early discovery toward the clinic, including the spin-out Neuron23, which raised over USD 310 million. He has built innovative drug discovery platforms that have delivered several clinical candidates in CNS and oncology. He is the inventor on more than 35 patent families and Phase II drug candidates, with deep expertise in AI-guided drug design, medicinal chemistry, physico-chemistry and ADME, IP strategy, fundraising, licensing, and partnerships. His therapeutic focus includes CNS, oncology, inflammation, and ophthalmology.

Gergana Galabova, DVM, PhD – CSO

linkedin | researchgate

She holds a Doctor of Veterinary Medicine degree and a PhD in veterinary histology and endocrinology, with more than 25 years of experience in translational science and pharmacology. She has led preclinical programs from early discovery through IND-enabling studies and early clinical phases, and has a strong track record in securing non-dilutive funding, raising more than EUR 10 million in grants. Her expertise spans histology, in vitro and in vivo proof-of-concept models, and biomarker-driven translation, always with a focus on linking preclinical insights to clinical success. Gergana has been a driving force in international collaborations and consortia, with therapeutic expertise in CNS, oncology, inflammation, and cardiometabolic diseases.

Michael Thormann, PhD – CEO

linkedin | researchgate

He holds a PhD in Biochemistry and has more than 25 years of experience in drug discovery and company building. As founder and long-term CEO/CSO of Origenis GmbH, he successfully guided multiple assets from early discovery toward the clinic, including the spin-out Neuron23, which raised over USD 310 million. He has built innovative drug discovery platforms that have delivered several clinical candidates in CNS and oncology. He is the inventor on more than 35 patent families and Phase II drug candidates, with deep expertise in AI-guided drug design, medicinal chemistry, physico-chemistry and ADME, IP strategy, fundraising, licensing, and partnerships. His therapeutic focus includes CNS, oncology, inflammation, and ophthalmology.

Gergana Galabova, DVM, PhD – CSO

linkedin | researchgate

She holds a Doctor of Veterinary Medicine degree and a PhD in veterinary histology and endocrinology, with more than 25 years of experience in translational science and pharmacology. She has led preclinical programs from early discovery through IND-enabling studies and early clinical phases, and has a strong track record in securing non-dilutive funding, raising more than EUR 10 million in grants. Her expertise spans histology, in vitro and in vivo proof-of-concept models, and biomarker-driven translation, always with a focus on linking preclinical insights to clinical success. Gergana has been a driving force in international collaborations and consortia, with therapeutic expertise in CNS, oncology, inflammation, and cardiometabolic diseases.

Michael Thormann, PhD – CEO

linkedin | researchgate

He holds a PhD in Biochemistry and has more than 25 years of experience in drug discovery and company building. As founder and long-term CEO/CSO of Origenis GmbH, he successfully guided multiple assets from early discovery toward the clinic, including the spin-out Neuron23, which raised over USD 310 million. He has built innovative drug discovery platforms that have delivered several clinical candidates in CNS and oncology. He is the inventor on more than 35 patent families and Phase II drug candidates, with deep expertise in AI-guided drug design, medicinal chemistry, physico-chemistry and ADME, IP strategy, fundraising, licensing, and partnerships. His therapeutic focus includes CNS, oncology, inflammation, and ophthalmology.

Gergana Galabova, DVM, PhD – CSO

linkedin | researchgate

She holds a Doctor of Veterinary Medicine degree and a PhD in veterinary histology and endocrinology, with more than 25 years of experience in translational science and pharmacology. She has led preclinical programs from early discovery through IND-enabling studies and early clinical phases, and has a strong track record in securing non-dilutive funding, raising more than EUR 10 million in grants. Her expertise spans histology, in vitro and in vivo proof-of-concept models, and biomarker-driven translation, always with a focus on linking preclinical insights to clinical success. Gergana has been a driving force in international collaborations and consortia, with therapeutic expertise in CNS, oncology, inflammation, and cardiometabolic diseases.

Smart.Molecules

Bridging innovation from discovery to clinic.

Smart.Molecules

Bridging innovation from discovery to clinic.

Smart.Molecules

Bridging innovation from discovery to clinic.

Michael Thormann, PhD – CEO

Gergana Galabova, DVM, PhD – CSO

Michael Thormann, PhD – CEO

Gergana Galabova, DVM, PhD – CSO

Michael Thormann, PhD – CEO

Gergana Galabova, DVM, PhD – CSO

Contact Us

Contact Us

office@togapharma.com

office@togapharma.com